674 related articles for article (PubMed ID: 12052038)
1. Endocannabinoids in the central nervous system--an overview.
Fride E
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):221-33. PubMed ID: 12052038
[TBL] [Abstract][Full Text] [Related]
2. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
Snider NT; Walker VJ; Hollenberg PF
Pharmacol Rev; 2010 Mar; 62(1):136-54. PubMed ID: 20133390
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoids and the gut: new developments and emerging concepts.
Izzo AA; Sharkey KA
Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
[TBL] [Abstract][Full Text] [Related]
4. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
5. Psychopharmacology of the endocannabinoids: far beyond anandamide.
Pamplona FA; Takahashi RN
J Psychopharmacol; 2012 Jan; 26(1):7-22. PubMed ID: 21652605
[TBL] [Abstract][Full Text] [Related]
6. The neuropharmacology of cannabinoid receptor ligands in central signaling pathways.
Brunt TM; Bossong MG
Eur J Neurosci; 2022 Feb; 55(4):909-921. PubMed ID: 32974975
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators.
Brown I; Cascio MG; Rotondo D; Pertwee RG; Heys SD; Wahle KW
Prog Lipid Res; 2013 Jan; 52(1):80-109. PubMed ID: 23103355
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Hwang J; Adamson C; Butler D; Janero DR; Makriyannis A; Bahr BA
Life Sci; 2010 Apr; 86(15-16):615-23. PubMed ID: 19527737
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoids and the heart.
Hiley CR
J Cardiovasc Pharmacol; 2009 Apr; 53(4):267-76. PubMed ID: 19276990
[TBL] [Abstract][Full Text] [Related]
10. Cannabimimetic plants: are they new cannabinoidergic modulators?
Kumar A; Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Memo M; Mastinu A
Planta; 2019 Jun; 249(6):1681-1694. PubMed ID: 30877436
[TBL] [Abstract][Full Text] [Related]
11. Beyond THC and Endocannabinoids.
Pacher P; Kogan NM; Mechoulam R
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():637-659. PubMed ID: 31580774
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid signaling in health and disease.
Lu Y; Anderson HD
Can J Physiol Pharmacol; 2017 Apr; 95(4):311-327. PubMed ID: 28263083
[TBL] [Abstract][Full Text] [Related]
13. The role of the endogenous cannabinoid system in peripheral analgesia.
Guindon J; Beaulieu P
Curr Mol Pharmacol; 2009 Jan; 2(1):134-9. PubMed ID: 20021453
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders.
Iannotti FA; Di Marzo V; Petrosino S
Prog Lipid Res; 2016 Apr; 62():107-28. PubMed ID: 26965148
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs.
Di Marzo V; De Petrocellis L
Curr Med Chem; 2010; 17(14):1430-49. PubMed ID: 20166923
[TBL] [Abstract][Full Text] [Related]
16. Dual modulation of CNS voltage-gated calcium channels by cannabinoids: Focus on CB1 receptor-independent effects.
Lozovaya N; Min R; Tsintsadze V; Burnashev N
Cell Calcium; 2009 Sep; 46(3):154-62. PubMed ID: 19682741
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoids in nervous system health and disease: the big picture in a nutshell.
Skaper SD; Di Marzo V
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3193-200. PubMed ID: 23108539
[TBL] [Abstract][Full Text] [Related]
18. Endocannabinoids.
Suchopár Josef; Laštůvka Zdeněk; Mašková Simona; Alblová Miroslava; Pařízek Antonín
Ceska Gynekol; 2021; 86(6):414-420. PubMed ID: 35038882
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis.
Correa FG; Mestre L; Docagne F; Borrell J; Guaza C
Vitam Horm; 2009; 81():207-30. PubMed ID: 19647114
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?].
Saito VM; Wotjak CT; Moreira FA
Braz J Psychiatry; 2010 May; 32 Suppl 1():S7-14. PubMed ID: 20512266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
